March 26, 2020

Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics ...
Read more
March 25, 2020

Orexo has repurchased 14 percent of own corporate bonds

Uppsala, Sweden – March 25, 2020. Orexo AB (publ.) has repurchased 14 percent of its outstanding unsecured corporate bonds with a nominal value of SEK 40,500,000 through ...
Read more
March 24, 2020

The Lancet Haematology Publishes Results from Oncopeptides’ Multicenter, International Phase 1/2 Study (O-12-M1)

Stockholm — March 24, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the publication of results from its O-12-M1 study, melflufen plus dexamethasone in r...
Read more
March 23, 2020

First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models

Study highlights previously untapped potential of genetically engineered macrophages in immunotherapy for solid tumors PHILADELPHIA, March 23, 2020 /PRNewswire/ -- Carisma Th...
Read more
March 23, 2020

Fusion Pharmaceuticals Appoints James J. O’Leary, M.D. As Chief Medical Officer

Boston, MA & Hamilton, ON – March 23, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as p...
Read more
March 23, 2020

Dr. Matthias Friebe joins Camel-IDS as acting Chief Technology Officer

Brussels (Belgium), 23 March 2020 Brussels, Belgium – Camel-IDS, a private biotechnology company developing novel radioligand therapies in oncology, announces t...
Read more
March 23, 2020

Accelerated road to market approval for CERAMENT® G in the US – BONESUPPORT[TM] submits De Novo application

Lund, Sweden, 8 am CET, 23 March 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company will sub...
Read more
March 23, 2020

Nordic Nanovector Appoints Dr Dominic Smethurst as Interim Chief Medical Officer

Oslo, Norway, 23 March 2020 Nordic Nanovector ASA (OSE: NANO) announces that Dr Dominic Smethurst has been appointed Interim Chief Medical Officer with immediate effec...
Read more
March 20, 2020

Oncopeptides provides update regarding COVID-19 impact on the melflufen clinical program

STOCKHOLM — March 20, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today measures the company is taking in response to the global spread of the novel coronav...
Read more
March 20, 2020

Vicore informs on clinical programs in relation to the current outbreak of COVID-19

Gothenburg, March 20, 2020 – Vicore Pharma informs on clinical programs in relation to the current outbreak of COVID-19. The on-going clinical study of Raynaud’s pheno...
Read more